|
Volumn 4, Issue 2, 2012, Pages 274-280
|
The Cabilly patents: Status quo and relevance for antibody companies
|
Author keywords
Antibody; Expression; Heavy; Lifetime; Light; Patent; Variable
|
Indexed keywords
ANTIBODY;
BELIMUMAB;
CHIMERIC ANTIBODY;
DIABODY;
ETANERCEPT;
MONOCLONAL ANTIBODY;
NANOBODY;
OFATUMUMAB;
SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;
TOSITUMOMAB;
UNCLASSIFIED DRUG;
BIOTECHNOLOGICAL PRODUCTION;
CONFLICT OF INTEREST;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG MARKETING;
EUROPE;
FOOD AND DRUG ADMINISTRATION;
LAW SUIT;
NONHUMAN;
PATENT;
REVIEW;
UNITED STATES;
ANIMAL;
HUMAN;
LEGISLATION AND JURISPRUDENCE;
ANIMALS;
ANTIBODIES;
DRUG INDUSTRY;
EUROPE;
HUMANS;
PATENTS AS TOPIC;
UNITED STATES;
|
EID: 84858174057
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.4.2.19253 Document Type: Review |
Times cited : (3)
|
References (9)
|